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Breastfeeding is important for the development of the child. Many antibiotics are 
considered safe during breastfeeding. The aim of the study was to assess the quality of 
lactation studies with antibiotics using the FDA and International Lacation Consultant 
Association (ILCA) quality guidelines for lactation studies. The secondary goal was to 
determine the exposure of the breastfed infant to antibiotics in relation to bacterial 
resistance and the developing microbiome. 
 
A literature search was performed and the included studies were scored on 
methodology, parameters concerning maternal exposure to antibiotics, maternal plasma 
and milk sampling. The infant exposure has been calculated and expressed as a 
percentage of a normal infant therapeutic dose.  
 
Sixty-six studies were included in 5 antibiotic groups (broad-spectrum penicillin, 
cephalosporins, macrolides and lincosamides, quinolones and sulfonamides). 
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the criteria of ‘mother exposure to antibiotic’. Six studies met every criterion related to 
‘plasma sampling’. Only one case-report met all listed criteria for lactation studies. The 
correct calculation of infant exposure to antibiotics via the milk:plasma  ratio (AUC) 
varies between 13% for macrolides and 38% for broad-spectrum penicillin. The highest 
assessed exposure as a percentage of infant therapeutic dose was for metronidazole 
(11%). 
 
The studies meet to a limited extent with the quality standards for lactation research. The 
breastfed infants are exposed to a sub-therapeutic concentration of antibiotics.  
 
Keywords: Infancy • Antibiotics • Breastfeeding • Microbiome  
 
Introduction 
Breastfeeding has numerous advantages over infant formula milk for the development of the 
neonate and decreases health risks of the nursing mother. Breastfeeding protects the 
neonate against child infections and malocclusions, increased intelligence at later age and 
protects against overweight and diabetes. For the mother, breastfeeding protects against 
breast cancer, ovarian cancer and type II diabetes (1). 
  
The World Health Organization recommends breastfeeding exclusively during the first six 
months and as a supplement up to 2 years. This is due to the earlier mentioned benefits and 
the low costs for the developing world. In the United States, 75% of mothers breastfeed their 
infants in the early post-partum period and 36% are exclusively breastfeeding at 3 months 
(2). One of the concerns in the lactation period is the safety of drugs being used by mothers, 
because transfer of the drug over the mammary gland may lead to side effects in the 
suckling infant. 
 
Antibiotics are probably among the most prescribed drugs during lactation. The prevalence 
of mastitis treated with antibiotics in lactating women is estimated between 16 and 49% 
(3,4). Most antibiotics are considered to be safe during breastfeeding, except quinolones, 
chloramphenicol, aminoglycosides during early postnatal period and possibly metronidazole 
(5,6).  
 
Nowadays, resistance to antibiotic drugs forms a great problem. Studies in both humans and 
animals show that low-dose exposure or inadequate exposure time to antibiotics correlates 
to the development of resistant microbes (7-9). Therefore, (long-term) sub-therapeutic 
transmission of antibiotics via breast milk to the infant could possibly contribute to antibiotic 
resistance in the infant. However, no data establishing this relation could be found. 
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antibiotics (10-13) and maternal use of antibiotics in the lactation period (14). In turn, the 
microbiome may affect brain development, behaviour and obesity (15-17). 
 
To assess the safety of antibiotics in the light of the developing microbiome, it is of 
paramount importance to know the amount of antibiotics transferred into breast milk which 
reaches the neonatal gastrointestinal tract. The most important parameter for the exposure 
of an infant to maternal use of antibiotics is the Absolut Infant Dose (AID) of which the 
formula is described in fig. 1. By calculating the AID, the infant dose per kilogram per day is 
known. Furthermore, the AID can be compared with the therapeutic infant dose.  
 
Objective and rationale  
In this study we aimed, using guidelines of the FDA (18) and ILCA (19), to determine the 
quality of lactation studies that investigated antibiotics in breast milk and examined the data 
regarding absolute infant dose.  
 
Search methods  
Antibiotics 
A literature search was performed using the PubMed database using the following search 
strings: (Milk, Human[MeSH Terms] OR Breast Milk[Title/Abstract] OR Human 
Milk[Title/Abstract]) or Lactation AND (a specific antibiotic drug (table 2)). See appendix 1 for 
detailed search strings. Cross references were searched for additional studies. An additional 
search was performed using the LactMed® database. Antibiotics were categorized in 17 
groups based on their chemical and physical properties (table 2). 
 
Inclusion and exclusion criteria  
Only articles containing primary data in humans published from 1970 until March 2017 were 
included in this study. We excluded studies of languages other than English, German and 
Dutch. Studies without reported drug concentrations in the mother’s plasma or mother’s milk 
were also excluded.  
 
Guidelines  
The FDA (18) and ILCA (19) draft guidelines were used to review the quality of the included 
articles. These guidelines provide recommendations on how to conduct clinical lactation 
studies. In more detail, information is given about the recommended study design and the 
data analysis that is favoured. In this MiniRreview, the recommendations of the FDA and 
ILCA were combined to create a checklist (table 1). Due to the limited amount of studies 
available per antibiotic, solely the results of antibiotic groups containing a minimum of 5 
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Absolute infant dose 
We determined the AIDs that are known for each group of antibiotics, by using the reported 
values or by calculating using the formula provided in fig. 1, using 150ml/kg/day as a 
standard for daily milk intake (20). We used a mean value for the AID for two published 
reports and a median value for three or more reports. The AID as a percentage of the 
Therapeutic Infant Dose (mg/kg/day) was calculated using the pediatric drug formulary of the 
Netherlands (21).  
 
Outcomes 
Using the search strings, we found 229 articles in the LactMed database and 808 articles in 
PubMed. In total, 174 articles and 797 articles were excluded in LactMed and PubMed, 
respectively. Reasons for exclusion were different language (n=127), no concentrations 
(n=254), review (n=169), animal study (n=258), paper published before 1970 (n=38), already 
in LactMed database (n=76) and duplicates (n=49) (fig. 2). We found no  studies that met the 
inclusion criteria for the antibiotics of the groups ‘Trimethoprim and similar compounds’ and 
‘Polymixins’ (table 2). In total, 66 studies were assessed using the checklist based on FDA 
(18) and ILCA (19,22) guidelines (table 1). For five antibiotic groups, only 1 study (23-27) 
was included and for three antibiotic groups, 2 studies (28-31) were included. The results of 
the quality determination of the different parameters (table 1) of 6 antibiotic groups with at 
least 5 studies are shown in fig. 3A-D. 
 
The parameters (table 1) that most frequently met the quality criteria set by combining the 
FDA and ILCA guidelines are the reported daily dose and dose regimen, see fig. 3A. 
Shortcomings of most studies were the absence of whole milk portions, see fig. 3B. 
  
Fifteen studies (23,27,29,32-43) met all the criteria of ‘mother exposure to drug’; this 
includes the presence of the administered daily dose and dose regimen, the analysis of 
concentrations during steady state and the use of longitudinal data (table 1). In only one 
case-report study with cephalexin (32), the breast milk sampling met all listed criteria. In six 
of the 66 assessed studies (37,38,42,44-46), every criterion related to ‘plasma sampling’ 
(table 1) was present. Only one study with cephalexin (32) met all the criteria of ‘method / 
data analysis’, including M:P, RID and AID are correctly measured and a validated method 
of analysis is used. Infant’s plasma concentrations or the occurrence of adverse reactions in 
the breastfeeding infant were only addressed in 10 of the 66 assessed studies 
(23,31,32,42,45,47-51).  
 
Next to the quality determination, we also assessed the potential infant risk based on the 
Absolute Infant Dose (AID) for different antibiotic drugs (fig. 4A). The highest AID 
corresponded to sulfapyridin (median AID: 2.68 mg/kg/day (N=4)) (37,45,52,53). The infant 
risk as a percentage of the daily therapeutic infant dose (fig. 4B) was the highest for 
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Wider implications 
Of all assessed antibiotic groups, cephalosporins was the most documented group, with 21 
different studies, including 226 patients (table 2). The data on the quality determination (fig. 
3) also reveal a prominent place for cephalosporins in relation to the validation criteria (table 
1). This could be related to the fact that cephalosporins are frequently used antibiotics in 
hospitals and especially in gynaecological care departments (56-58), with attendance of 
nursing mothers. Most other antibiotics are poorly studied like broad-spectrum penicillins (8 
studies, 78 patients), sulfonamides (5 studies, 27 patients) macrolides and lincosamides (8 
studies, 67 patients) and quinolones (7 studies, 59 patients). 
 
Many studies lack information about the sample size, method of collection (electric pump or 
‘normal’) and whether foremilk or hindmilk was sampled. Without a standardized method of 
collection, it is hard to compare studies examining transfer of drugs into breast milk. A 
differentiation between foremilk and hindmilk collection is necessary, which was only 
performed in 6 studies (30,32,41,59-61). Hindmilk is more lipophilic than foremilk; therefore, 
lipophilic antibiotics like quinolones, macrolides and tetracyclines will probably penetrate 
more easily into hindmilk (62-64). This might result in an under- or over-estimation of 
antibiotic concentrations in breast milk.  
 
Calculated parameters related to drug transfer into breast milk (M:P ratio, AID, RID) are 
poorly studied in the assessed lactation studies. The correct measurement of the M:P ratio 
varies between 13% of the studies for macrolides and lincosamides and 38% of the studies 
for broad-spectrum penicillin. The M:P ratio is often calculated as single point milk:plasma 
concentrations, where whole “area under the curve” of the milk/plasma curve is by far more 
accurate. However, the clinical implication of the M:P ratio is over-estimated because a low 
absolute dose with a high M:P ratio means that still a small amount of a particular drug can 
be found in the milk.  The poor establishment of drug transport over the mammary gland 
may be related to the absence of measurements in steady-state conditions and concurrent 
sampling of plasma and milk in many studies.  
 
In order to assess the infant risk to different antibiotics, when transferred into breast milk, we 
presented, or when necessary, calculated the Absolut Infant Dose (AID). The highest 
exposure in breast milk was found for sulfapyridin (2.68 mg/kg/day) based on an average 
milk intake of 150ml/kg/day. This sulfonamide seems compatible with breastfeeding, when 
the infant shows no signs of illness, stress or jaundices (5,65,66). However, based on 
primarily the AID, it is hard to review the risk for the infant. Therefore, we calculated the AID 
as a percentage of the daily therapeutic dose. The AID in perspective of the therapeutic 
infant dose for metronidazole (11% of therapeutic dose), ofloxacin (2% of therapeutic dose) 
and gentamycin (2% of therapeutic dose) (fig. 4B), would relate to the highest risk for the 
breastfeeding infant. For metronidazole, which is indicated for anaerobic infections, 
especially for prophylaxis following caesarian section and post-partum infection control (67-
69), no breastfeeding is advised upon 12-24 hr after the last metronidazole dose (66). 
However, only one case-report describes infant diarrhoea after breast milk consumption of a 
mother exposed to metronidazole (70). Based on these percentages alone, it is hard to 
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drugs, minimalizing infant exposure also applies for maternal use of antibiotics and 
monitoring for possible adverse reactions is needed. However, only in 6 studies adverse 
reactions were documented using standardized methods (23,31,32,42,47,49). General 
concerns of maternal use of antibiotics for the infant are in potential for allergic reaction, 
changes in bowel flora, and confounding of culture results by the ingested antibiotic if a fever 
work-up is performed for the infant.  
 
Specific for ampicillin, diarrhoea and candidiasis have been reported in nursing infants. 
Moxalactam, a third-generation cephalosporin, may lead to colonization of infant’s bowel 
with gram-positive organisms is possible, resulting in a risk for enterocolitis.  (71) 
 
Diarrhoea, irritability and pyloric stenosis have been reported for erythromycin in nursing 
infants. Perforated pseudomembranous colitis was reported in a breastfed infant whose 
mother used ciprofloxacin. For sulfasalazine, there is a risk of bilirubin displacing, and bloody 
diarrhoea has been reported in the nursing infant of a mother who was a slow acetylator. For 
chloramphenicol, refusal of the breast, somnolence during feeding, gas and post-feeding 
emesis have been reported in nursing infants. For metronidazole loose stools, feeding 
problems, and candidiasis have been reported in nursing infants. (65) 
 
The use of maternal antibiotics could also play a role in bacterial resistance and modification 
of the infant microbiome. As mentioned earlier, sub-therapeutic dosing of antibiotics is 
associated with the development of resistant microorganisms (7-9). Based on our results, all 
assessed antibiotics (fig. 4B) are transferred into breast milk in sub-therapeutic levels 
ranging from 0.05% for cefotaxime to 10.61% for metronidazole of the therapeutic infant 
dose. This low-dose exposure might induce antibiotic resistance in the infant and might lead 
to a reduced diversity of intestinal microbiota during infancy and the occurrence of allergies 
later in life (72-74), and contribute to the development of infant diseases, even later in life, 
like disturbances in brain development, immunity, behaviour and obesity (15-17,75,76). Also, 
the infant colonization rate of microorganisms is affected by maternal use of antibiotics in the 
lactation period (77), which is one of the first signs of altered gut microbiota composition. 
The safety of maternal use of antibiotics in relation to the infant’s microbiome and its effects 
later in life should be further studied.  
 
Conclusion 
This MiniReview assessed the quality of lactation studies according to FDA and ILCA 
guidelines, and most studies did not comply with these guidelines. Especially,  the study 
methodology was poorly described. We found that antibiotics like metronidazole with a 
relatively high AID of 11% of the therapeutic infant dose, is suspected of  antibiotic 
resistance and microbiome alterations in the suckling infant. However, further research on 
these effects in breastfeeding infants is needed. In the meantime, the benefits of maternal 
antibiotic therapy should be weighed against the potential (long-term) risk for the 
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Figure 1. Formulas for the calculation of  M:P, AID and RID, according to the ILCA guidelines. In 


















































Figure 3. Quality determination of the lactation studies of different antibiotic groups.  
For different parameters based on FDA (18) and ILCA (19) guidelines, the percentage of correctly 
performed studies is presented. Studies are scored based on parameters related to drug exposure of 
the mother (A), plasma sampling parameters (B), milk sampling parameters (C) and method/analytic 










































































Figure 4. Absolute Infant Dose for different antibiotic drugs.  
Presented is the Absolute Infant Dose (mg/kg/day) for 57 different antibiotic drugs, when a daily infant 
milk intake of 150ml/kg/day is used (20). (A) and Absolute Infant Dose as a percentage of the 
Therapeutic Infant Dose (mg/kg/day) for 20 different antibiotic drugs (B). A mean AID based on data 
from 2 different studies was calculated for Tetracycline, Chloramphenicol, Ceftriaxone, Ciprofloxacin 
and Tinidazole. A median AID based on data from 3 different studies was calculated for Cefotaxime, 
Cephalexin, Clindamycin, Azithromycin Metronidazole,and Nitrofurantoin. A median AID based on 
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Table 1. Checklist for the quality of lactation studies involving antibiotic use, based on the ILCA (19) 
and FDA (18) guidelines. 
Subject Explanation 
Study design  
Number of patients No FDA and ILCA recommendations 
Full article  No FDA and ILCA recommendations 
  
Mother exposure to drug  
Daily dose given Daily dose exposure to the mother is known 
Dose regimen given Dose regimen is known 
Steady state Rate of drug absorption is equal to rate of drug 
elimination 
Longitudinal data Samples are obtained between two postpartum 
periods in individual woman for drugs that are 
administered chronically in several treatment cycles 
  
Breast milk sampling  
Time compared to drug intake 
known 
Time between administration of the drug and 
sampling is known 
Multiple measures in dose 
interval 
Minimum 5 samples are taken more than one hour 
from each other 
Full method of collection given Method including; how milk is withdrawn (manual or 
electric), sample volume, milk type (pre- or 
postfeeding) 
Representive for for and hind 
milk 
Samples are taken from for and hindmilk 
Both breast Both breast are sampled 
  
Plasma sampling  
Plasma levels measured Mothers plasma level of the drug is known 
Sampled concomitted with milk Plasma is simultaneously sampled with breast milk  
Multiple measures in dose 
interval 
Minimum 5 samples are taken more than one hour 





























Metabolites taken into account Drug metabolites are analysed 
  
  
Method / Data analysis  
M:P correctly measured  The antibiotic concentration in breast milk divided by 
the antibiotic concentration in mother’s plasma (fig. 1) 
RID and AID correctly 
measured 
AID: the absolute amount of antibiotic consumed by 
the infant per kilogram per day (fig. 1) 
RID: infant drug exposure as a percentage of the 
maternal dose normalized by the maternal and infant 
weight (fig. 1) 
Method analysis given, 
validated  
Method of sample analysis is given and a validated 
method is used. 
Child observation  
Plasma level known in child Drug plasma levels of the infant are known 
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Registered and unregistered antibiotics categorized by group (antibiotic group name in bold) 
TETRACYCLINS  BETALACTMASE SUSCEPTIBLE SULFATHIAZOLE TELITHROMYCIN CEFPODOXIME NORFLOXACIN  MURIPOCIN 
DEMECLOCYCLINE  PENICILLINS  SULFAMETHOXAZOLE CLINDAMYCIN (28,59,78) CEFACETRILE LOMEFLOXACIN TEDIZOLID 
DOXYCYCLINE (30) BENZYLPENICILLIN (28) SULFADIAZINE LINCOMYCIN  CEFROXADINE (28) FLEROXACIN (46) NIFURTOINOL 
CHLORTETRACYCLINE PHENOXYMETHYLPENICILLIN (31)  SULFAMOXOLE CEPHALOSPORINS CEFTEZOLE SPARFLOXACIN FOSFOMYCIN 
LYMECYCLINE PROPICILLIN SULFADIMETHOXINE CEFALOTIN (79) CEFPIROME RUFLOXACIN XIBORNOL 
METACYCLINE  PENAMECILLIN SULFALENE CEFAZOLIN  (80,81) CEFIXIME GREPAFLOXACIN CLOFOCTOL 
OXYTETRACYCLINE CLOMETOCILLIN SULFAMETOMIDINE CEFOXITIN  (28,49,82-84) CEFEPIME LEVOFLOXACIN (39) SPECTINOMYCIN 
TETRACYCLINE (28,30) BENZYLPENICILLINEBENZATHIN SULFAMETHOXYDIAZINE CEFUROXIME CEFODIZIME TROVAFLOXACIN METHENAMINE (61) 
MINOCYCLINE AZIDOCILLIN SULFAMETHOXYPYRIDAZINE CEFAMANDOL CEFETAMET MOXIFLOXACIN NITROXOLIN 
ROLITETRACYCLINE FENETICILLIN  SULFAPERIN CEFACLOR CEFPIRAMIDE GEMIFLOXACIN LINEZOLID (41) 
PENIMEPICYCLINE BETALACTMASE RESISTENT  SULFAMERAZINE CEFADROXIL  (28,79) CEFAPIRINE (79) GATIFLOXACIN DAPTOMYCIN (85) 
CLOMOCYCLINE PENICILLINS SULFAFENAZOLE CEFOTAXIME  (28,79,86,87) CEFRADINE (88) PRULIFLOXACIN FIDAXOMICIN 
TIGECYCLINE DICLOXACILLIN SULFAMAZONE CEFTIBUTEN (89) CEFOPERAZONE  (28) PAZUFLOXACIN ORNIDAZOLE 
AMPHENICOLS CLOXACILLIN SULFAMETROLE CEFDINIR AMINOGLYCOSIDEN GARENOXACIN (90) NITROFURANTOIN (91-93) 
CHLORAMPHENICOL (28,29) METICILLIN SULFAMETOPYRAZINE CEFMETAZOLE (28) STREPTOMYCIN ROSOXACIN  
THIAMPHENICOL (29) OXACILLIN (27) SULFAFURAZOLE CEFPROZIL (94) STREPTODUOCIN NALIDIXIN (95)  
BROAD SPECTRUM PENICILLINS FLUCLOXACILLIN SULFANILAMIDE CEFORANID TOBRAMYCIN (96) PIROMIDIN  
AMPICILLIN (27,28,44,47) FLOXACILLIN SULFADIMIDINE CEFTIZOXIME (28) GENTAMICIN (50) PIPEMIDIN  
PIVAMPICILLIN (48) BETALACTMASE INHIBITORS SULFAPYRIDINE (37,45,52,53,97) CEFDITOREN KANAMYCIN (28) OXOLIN  
CARBENICILLIN (28) SULBACTAM (26) MACROLIDES AND  CEFTAROLINE  NEOMYCIN CINOXACIN  
AMOXICILLIN (79) TAZOBACTAM LINCOSAMIDES CEFTOLOZAN AMIKACIN (28) FLUMEQUINE  
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Table 2. List of included antibiotics in this MiniReview. References of the included antibiotics are presented in brackets. No studies were included for the 
antibiotics without references.  
 
 
BACAMPICILLIN (28) AZTREONAM (25) SPIRAMYCIN  LORACARBEF SISOMICIN VANCOMYCIN (23)  
EPICILLIN (88) CARBAPENEM-ANTIBIOTICS MIDECAMYCIN CEFSULODIN DIBEKACIN TEICOPLANIN  
PIVMECILLINAM  MEROPENEM (24) PRISTINAMYCIN CEFTRIAXONE (36,79) RIBOSTAMYCIN TELAVANCIN  
AZLOCILLIN ERTAPENEM OLEANDOMYCIN CEFOTETAN (28) ISEPAMICIN DALBAVANCIN  
MEZLOCILLIN (28) DORIPENEM  ROXITHROMYCIN (98) CEFAZEDON FRAMYCETIN ORITAVANCIN  
MECILLINAM IMIPENEM JOSAMYCIN(28) CEFMENOXIME (33) PAROMOMYCIN POLYMYXINS  
PIPERACILLIN TRIMETHOPRIM AND SIMILAR  TROLEANDOMYCIN CEFONICID (99) STREPTOZOCIN COLISTIN  
TICARCILLIN (28,100) COMPOUNDS CLARITHROMYCIN (38) LATAMOXEF QUINOLONES POLYMYXIN B  
METAMPICILLIN TRIMETHOPRIM  AZITHROMYCIN (101-103) MOXALACTAM (35) OFLOXACIN (40) BACTRACIN  
TALAMPICILLIN BRODIMOPRIM MIOCAMYCIN CEFOTIAM (28) CIPROFLOXACIN 
(40,51,104) 
GRAMICIDIN  
SULBENICILLIN (28)  SULFONAMIDES ROKITAMYCIN  CEFATRIZINE PEFLOXACIN (40) OTHERS ANTIBIOTICS  
TEMOCILLIN SULFISOMIDINE DIRITHROMYCIN CEPHALEXIN (28,32,79) ENOXACIN METRONIDAZOLE 
(42,43,54,55)[42, 43, 55, 
56][42, 43, 55, 56](Passmore 
et al., 1988; Heisterberg and 
Branebjerg, 1983; Erickson et 
al., 1981; A. T. Willis, I. R. 
Ferguson, P. H. Jones, K. D. 
Phillips, P. V. Tearle, 1978) 
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Appendix 1 – detailed search parameters 
 
("Milk, Human"[Mesh] OR "Breast Milk"[title/abstract] OR "Human Milk"[title/abstract] OR 
LACTATION [TITLE/ABSTRACT]) AND  
 
TETRACYCLINES 
(DEMECLOCYCLIN* OR DOXYCYCLIN* OR CHLORTETRACYCLIN* OR LYMECYCLIN* OR 
METACYCLIN* OR OXYTETRACYCLIN* TETRACYCLIN* OR MINOCYCLIN* OR  
ROLITETRACYCLIN* OR PENIMEPICYCLIN* OR CLOMOCYCLIN* TIGECYCLIN*) 
  
AMPHENICOLES 
(CHLORAMPHENICOL* OR THIAMPHENICOL*) 
 
BROAD SPECTRUM PENICILLIN 
(AMPICILLIN* OR PIVAMPICILLIN* OR CARBENICILLIN*  OR AMOXICILLIN* OR CARINDACILLIN* 
OR BACAMPICILLIN* OR EPICILLIN* OR PIVMECILLINAM* OR  AZLOCILLIN* OR MEZLOCILLIN*  
OR MECILLINAM* OR PIPERACILLIN* OR TICARCILLIN* OR METAMPICILLIN* OR 
TALAMPICILLIN* OR  SULBENICILLIN* OR TEMOCILLIN* OR HETACILLIN*) 
 
BETA-LACTAMASE-SENSITIVE PENICILLIN 
(BENZYLPENICILLIN* OR FENOXYMETHYLPENICILLIN* OR PHENOXYMETHYLPENICILLIN* OR 
PROPICILLIN* OR AZIDOCILLIN* OR FENETICILLIN* OR PENAMECILLIN* OR CLOMETOCILLIN* 
OR BENZYLPENICILLINEBENZATHIN* OR (PENICILLIN* V) OR (PENICILLIN* G)) 
 
BETA-LACTAMASE-RESISTENT PENICILLIN 




(SULBACTAM OR TAZOBACTAM) 
 
CEFALOSPORINS  
(CEFALEXIN* OR CEFALORIDIN* OR CEFALOTIN* OR CEFAZOLIN* OR CEFOXITIN* OR 
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CEFTAZIDIM* OR CEFSULODIN* OR CEFTRIAXON* OR CEFOTETAN* OR CEFAZEDON* OR 
CEFMENOXIM* OR CEFONICID* OR LATAMOXEF* OR MOXALACTAM OR CEFOTIAM* OR 
CEFATRIZIN* OR CEFIXIM* OR CEFEPIM* OR CEFODIZIM* OR CEFETAMET* OR CEFPIRAMID* 
OR CEFAPIRIN* OR CEFRADIN* OR CEFOPERAZON* OR CEFPODOXIM* OR CEFACETRIL* OR 
CEFROXADIN* OR CEFTEZOL* OR CEFPIROM* OR LORACARBEF* OR CEFTIBUTEN OR 
CEFDINIR* OR CEFMETAZOL* OR CEFPROZIL* OR CEFORANID* OR CEFTIZOXIM* OR 






(MEROPENEM OR ERTAPENEM OR DORIPENEM OR IMIPENEM) 
 
TRIMETHOPRIM AND DERIVATIVES 
(TRIMETHOPRIM OR BRODIMOPRIM) 
 
SULFONAMIDES 
(SULFISOMIDIN* OR SULFAMETHIZOL* OR SULFADIMIDIN* OR SULFAPYRIDIN* OR 
SULFAFURAZOL* OR SULFANILAMID* OR SULFATHIAZOL* OR SULFAMETHOXAZOL* OR 
SULFADIAZIN* OR SULFAMOXOL* OR SULFADIMETHOXIN* OR SULFALEEN OR 
SULFAMETOMIDIN* OR SULFAMETHOXYDIAZIN* OR SULFAMETHOXYPYRIDAZIN* OR 
SULFAPERIN* OR SULFAMERAZIN* OR SULFAFENAZOL* OR SULFAMAZON* OR 
SULFAMETROL* OR SULFAMETOPYRAZIN*) 
 
MACROLIDE ANTIBIOTICS AND LINCOSAMIDE 
(ERYTHROMYCIN* OR SPIRAMYCIN* OR MIDECAMYCIN* OR PRISTINAMYCIN* OR 
OLEANDOMYCIN* OR ROXITHROMYCIN* OR JOSAMYCIN* OR TROLEANDOMYCIN* OR 
CLARITHROMYCIN* OR AZITHROMYCIN* OR MIOCAMYCIN* OR ROKITAMYCIN* OR 




(STREPTOMYCIN* OR STREPTODUOCIN* OR TOBRAMYCIN* OR GENTAMICIN* OR 
KANAMYCIN* OR NEOMYCIN* OR AMIKACIN* OR NETILMICIN* OR SISOMICIN* OR DIBEKACIN* 
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QUINOLONES 
(OFLOXACIN* OR CIPROFLOXACIN* OR PEFLOXACIN* OR ENOXACIN* OR TEMAFLOXACIN* 
OR NORFLOXACIN* OR LOMEFLOXACIN* OR FLEROXACIN* OR SPARFLOXACIN* OR 
RUFLOXACIN* OR GREPAFLOXACIN* OR LEVOFLOXACIN* OR TROVAFLOXACIN* OR 
MOXIFLOXACIN* OR  GEMIFLOXACIN* OR GATIFLOXACIN* OR PRULIFLOXACIN* OR 
PAZUFLOXACIN* OR GARENOXACIN* OR ROSOXACIN* OR NALIDIXIN* OR PIROMIDIN* OR 




(VANCOMYCIN* OR TEICOPLANIN* OR TELAVANCIN* OR DALBAVANCIN* OR ORITAVANCIN*) 
 
POLYMYXINS 
(COLISTIN* OR “POLYMYXIN B” OR BACTRACIN* OR GRAMICIDIN*) 
 
ADDITIONAL ANTIBIOTICS 
(METRONIDAZOL* OR TINIDAZOL* OR ORNIDAZOL* OR NITROFURANTOIN* OR NIFURTOINOL 
OR FOSFOMYCIN* OR PHOSPHOMYCIN* OR XIBORNOL* OR CLOFOCTOL* OR 
SPECTINOMYCIN* OR METHENAMIN* OR NITROXOLIN* OR LINEZOLID OR DAPTOMYCIN* OR 
FIDAXOMICIN* OR MURIPOCIN* OR TEDIZOLID) 
 
ANTITUBERCULOUS DRUGS  
(AMINOSALICYL* OR CYCLOSERIN* OR RIFAMPICIN* OR RIFAMYCIN* OR RIFABUTIN* OR 
RIFAPENTIN* OR RIFAXIMIN* OR CAPREOMYCIN* OR ISONIAZID* OR PROTIONAMID* OR 
TIOCARLID* OR ETHIONAMID* OR PYRAZINAMID* OR ETHAMBUTOL OR TERIZIDON* OR 
MORINAMID* OR BEDAQUILIN* OR DELAMANID) 
 
 
